Menu
Recruiting NCT06953622

Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale

Observational Migraine Patent Foramen Ovale

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Conservative treatment, Antipaletet drug, Patent Foramen Ovale Closure.
Who it may be relevant to
Registry conditions: Migraine, Patent Foramen Ovale. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

To establish a headache center in China that combines clinical, imaging and laboratory examinations, explore the feasible treatment options for migraine combined with patent foramen ovale, and search for the possible influencing factors, construct models that influence prognosis.

Interventions

  • Drug Conservative treatment
    Receive no antipaletet drug treatment and surgery
  • Drug Antipaletet drug
    Use of antipaletet drugs.
  • Procedure Patent Foramen Ovale Closure
    Receive the surgery of Patent Foramen Ovale

Primary outcome measures

  • The changes of migraine attacks [Time frame: 3 months, 6 months, 1 year, 2 years and 3 years]

Eligibility criteria

Inclusion criteria

  • Meet the diagnostic criteria for migraine in the International Classification of Headache (ICHD-3);
  • Confirmation of patent foramen ovale through transthoracic echocardiography(TTE) or transesophageal echocardiography(TEE)/right heart contrast echocardiography
  • Agree to participate in the study and sign the informed consent form.

Exclusion criteria

  • Can not sign the informed consent form or cooperate with follow-up.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Peking University Third Hospital — Beijing

Identifiers

NCT: NCT06953622 · M2024296

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗